Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23153646,flow rate of the mobile phase,"The flow rate of the mobile phase was 200 μL/min and the retention times of tamsulosin and the internal standard (IS, diphenhydramine) were 0.8 and 0.9 min, respectively.",Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153646/),[μl] / [min],200,2163,DB01075,Diphenhydramine
,23153646,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of tamsulosin and the internal standard (IS, diphenhydramine) were 0.8 and 0.9 min, respectively.",Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153646/),min,0.8,2164,DB01075,Diphenhydramine
,23153646,retention times,"The flow rate of the mobile phase was 200 μL/min and the retention times of tamsulosin and the internal standard (IS, diphenhydramine) were 0.8 and 0.9 min, respectively.",Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153646/),min,0.9,2165,DB01075,Diphenhydramine
,19523012,clearance (CL),"The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively.",A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523012/),[l] / [h],24.7,5959,DB01075,Diphenhydramine
,19523012,apparent volume of distribution (V(d)),"The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively.",A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523012/),l,302,5960,DB01075,Diphenhydramine
,19523012,apparent terminal elimination half-life (t(1/2)),"The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively.",A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523012/),h,9.3,5961,DB01075,Diphenhydramine
,19523012,oral C(max),"The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively.",A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523012/),[ng] / [ml],0.195,5962,DB01075,Diphenhydramine
,19523012,AUC(0-infinity),"The median clearance (CL), apparent volume of distribution (V(d)) and apparent terminal elimination half-life (t(1/2)) of diphenhydramine after an i.v. microdose were 24.7 l h(-1), 302 l and 9.3 h, and the oral C(max) and AUC(0-infinity) were 0.195 ng ml(-1) and 1.52 ng h ml(-1), respectively.",A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19523012/),[h·ng] / [ml],1.52,5963,DB01075,Diphenhydramine
,17007366,flow rate,"Risperidone and the internal standard, diphenhydramine, were isolated from plasma by liquid-liquid extraction with etherdichloromethane (3:2, v/v) , then chromatographed on a Zorbax Extend-C18 column (150 mm x 4.6 mm ID, 5 microm) using a mobile phase consisted of acetonitrile-water-formic acid (40:60: 0.5, v/v), at a flow rate of 0.7 mL x min(-1).",[Determination of risperidone in human plasma by liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17007366/),[ml] / [min],0.7,7054,DB01075,Diphenhydramine
,18585287,flow rate,"The chromatographic separation was achieved using a Supelco C(18)-DB (250 mm x 4.6mm I.D./5 microm particle size) column with mobile phase comprising of ammonium acetate buffer and acetonitrile (63:37, v/v), delivered isocratically at a flow rate of 1.0 mL min(-1).",A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma--application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585287/),[ml] / [min],1.0,16964,DB01075,Diphenhydramine
,18585287,time of analysis,"The advantages of our method are small sample volume (100 microL), short time of analysis (13 min) and a simple sample extraction and clean-up as compared to the previously published methods.",A simple and rapid high performance liquid chromatographic method with fluorescence detection for the estimation of fexofenadine in rat plasma--application to preclinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585287/),min,13,16965,DB01075,Diphenhydramine
,20039385,elimination terminal half-life,MU1140 total plasma concentration-time profiles declined biexponentially with elimination terminal half-life of 1.6 +/- 0.1 h.,Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20039385/),h,1.6,17332,DB01075,Diphenhydramine
,9929519,hepatic first-pass extraction,The hepatic first-pass extraction of DPHM after p.v. administration was 94.2 +/- 3.7%.,Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9929519/),%,94.2,22316,DB01075,Diphenhydramine
,9929519,hepatic extraction,"Because the drug delivered to the hepatoportal system is almost completely eliminated in a single pass (hepatic extraction approximately 94%), this indicates a lack of any significant pulmonary drug uptake.",Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9929519/),%,94,22317,DB01075,Diphenhydramine
,9929519,gut extraction ratio,This gut contribution to systemic DPHM clearance was confirmed in a separate direct study in four sheep where the steady-state DPHM gut extraction ratio was 49.0 +/- 3.0%.,Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9929519/),%,49.0,22318,DB01075,Diphenhydramine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.15,26156,DB01075,Diphenhydramine
,3091779,peak ulcers,"These doses produced peak ulcers of 0.15 to 0.22 cm2, respectively, one to five days after injection.",Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2,0.22,26157,DB01075,Diphenhydramine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26158,DB01075,Diphenhydramine
,3091779,area X time,The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26159,DB01075,Diphenhydramine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,0.89,26160,DB01075,Diphenhydramine
,3091779,area under the curve [AUC],The integrated ulcer area X time values (area under the curve [AUC] ulceration) were 0.89 and 3.11 cm2 X d.,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),cm2·d,3.11,26161,DB01075,Diphenhydramine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],0.89,26162,DB01075,Diphenhydramine
,3091779,AUC,DMSO significantly increased the AUC for MMC in skin from 0.89 to 2.25 ng/h/mL of tissue (P less than .05).,Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3091779/),[ng] / [h·ml],2,26163,DB01075,Diphenhydramine
,7961108,half life,Pharmacokinetic studies performed using high-performance liquid chromatography demonstrated that plasma concentrations of paclitaxel increased during the 24-h infusion and declined immediately upon cessation of the infusion with a half life of 13.1-24.6 h (75-180 mg/m2).,Phase I and pharmacokinetic study of paclitaxel by 24-hour intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7961108/),h,13.1-24.6,29930,DB01075,Diphenhydramine
,3760245,volume of distribution,"Mean kinetic variables for DP after intravenous (IV) dosage were: volume of distribution, 4.5 L/kg; elimination half-life, 8.4 hours; clearance, 6.2 mL/min/kg.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),[l] / [kg],4.5,30101,DB01075,Diphenhydramine
,3760245,elimination half-life,"Mean kinetic variables for DP after intravenous (IV) dosage were: volume of distribution, 4.5 L/kg; elimination half-life, 8.4 hours; clearance, 6.2 mL/min/kg.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),h,8.4,30102,DB01075,Diphenhydramine
,3760245,clearance,"Mean kinetic variables for DP after intravenous (IV) dosage were: volume of distribution, 4.5 L/kg; elimination half-life, 8.4 hours; clearance, 6.2 mL/min/kg.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),[ml] / [kg·min],6.2,30103,DB01075,Diphenhydramine
,3760245,peak plasma level,"After oral DP administration, a peak plasma level of 66 ng/mL was reached 2.3 hours after dosage.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),[ng] / [ml],66,30104,DB01075,Diphenhydramine
,3760245,Systemic availability,"Systemic availability was 72%, nearly identical to the predicted estimate (71%) based on clearance of IV DP relative to hepatic blood flow.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),%,72,30105,DB01075,Diphenhydramine
,3760245,Systemic availability,"Systemic availability was 72%, nearly identical to the predicted estimate (71%) based on clearance of IV DP relative to hepatic blood flow.",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),%,71,30106,DB01075,Diphenhydramine
,3760245,AUC,"However, metabolite AUC was significantly higher after oral as opposed to IV DP (218 vs 145 hr-ng/mL, P less than .05).",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),[hr-ng] / [ml],218,30107,DB01075,Diphenhydramine
,3760245,AUC,"However, metabolite AUC was significantly higher after oral as opposed to IV DP (218 vs 145 hr-ng/mL, P less than .05).",Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760245/),[hr-ng] / [ml],145,30108,DB01075,Diphenhydramine
,8445526,steady-state drug concentration,"Average steady-state drug concentration in plasma after maternal infusion was 212.1 +/- 67.8 ng/mL in the mother and 36.3 +/- 14.4 ng/mL in the fetus, resulting in a fetal-to-maternal concentration ratio of 0.19 +/- 0.10.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ng] / [ml],212.1,31241,DB01075,Diphenhydramine
,8445526,steady-state drug concentration,"Average steady-state drug concentration in plasma after maternal infusion was 212.1 +/- 67.8 ng/mL in the mother and 36.3 +/- 14.4 ng/mL in the fetus, resulting in a fetal-to-maternal concentration ratio of 0.19 +/- 0.10.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ng] / [ml],36.3,31242,DB01075,Diphenhydramine
,8445526,fetal-to-maternal,"Average steady-state drug concentration in plasma after maternal infusion was 212.1 +/- 67.8 ng/mL in the mother and 36.3 +/- 14.4 ng/mL in the fetus, resulting in a fetal-to-maternal concentration ratio of 0.19 +/- 0.10.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),,0.19,31243,DB01075,Diphenhydramine
,8445526,concentration ratio,"Average steady-state drug concentration in plasma after maternal infusion was 212.1 +/- 67.8 ng/mL in the mother and 36.3 +/- 14.4 ng/mL in the fetus, resulting in a fetal-to-maternal concentration ratio of 0.19 +/- 0.10.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),,0.19,31244,DB01075,Diphenhydramine
,8445526,steady-state drug concentrations,"Following fetal infusions, maternal and fetal steady-state drug concentrations were 31.1 +/- 11.6 and 447.6 +/- 185.2 ng/mL, respectively.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ng] / [ml],31.1,31245,DB01075,Diphenhydramine
,8445526,steady-state drug concentrations,"Following fetal infusions, maternal and fetal steady-state drug concentrations were 31.1 +/- 11.6 and 447.6 +/- 185.2 ng/mL, respectively.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ng] / [ml],447.6,31246,DB01075,Diphenhydramine
,8445526,free fraction,The free fraction of diphenhydramine determined in the fetus (0.277 +/- 0.087) was significantly greater than that in the mother (0.141 +/- 0.079).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),,0.277,31247,DB01075,Diphenhydramine
,8445526,free fraction,The free fraction of diphenhydramine determined in the fetus (0.277 +/- 0.087) was significantly greater than that in the mother (0.141 +/- 0.079).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),,0.141,31248,DB01075,Diphenhydramine
,8445526,total fetal clearance,The total fetal clearance (472.7 +/- 215.7 mL/min) was relatively small compared with the total maternal clearance (3426.1 +/- 905.8 mL/min).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],472.7,31249,DB01075,Diphenhydramine
,8445526,total maternal clearance,The total fetal clearance (472.7 +/- 215.7 mL/min) was relatively small compared with the total maternal clearance (3426.1 +/- 905.8 mL/min).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],3426.1,31250,DB01075,Diphenhydramine
,8445526,transplacental clearance,The transplacental clearance from fetus to mother (264.4 +/- 138.7 mL/min) was approximately threefold higher than that from mother to fetus (82.4 +/- 40.5 mL/min).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],264.4,31251,DB01075,Diphenhydramine
,8445526,transplacental clearance,The transplacental clearance from fetus to mother (264.4 +/- 138.7 mL/min) was approximately threefold higher than that from mother to fetus (82.4 +/- 40.5 mL/min).,Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],82.4,31252,DB01075,Diphenhydramine
,8445526,nonplacental clearance,"Maternal nonplacental clearance (3343.8 +/- 890.7 mL/min) accounted for 97.8 +/- 1.1% of the maternal total clearance, whereas fetal nonplacental clearance (208.4 +/- 80.4 mL/min) accounted for 45.1 +/- 4.7% of the fetal total clearance.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],3343.8,31253,DB01075,Diphenhydramine
,8445526,nonplacental clearance,"Maternal nonplacental clearance (3343.8 +/- 890.7 mL/min) accounted for 97.8 +/- 1.1% of the maternal total clearance, whereas fetal nonplacental clearance (208.4 +/- 80.4 mL/min) accounted for 45.1 +/- 4.7% of the fetal total clearance.",Transplacental and nonplacental clearances of diphenhydramine in the chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8445526/),[ml] / [min],208.4,31254,DB01075,Diphenhydramine
,9869373,limits of detection,"Using 0.6-ml samples, the estimated limits of detection for R-(+)-bupivacaine and S-(-)-bupivacaine were both 15 ng/ml of blood.",High-performance liquid chromatographic separation and nanogram quantitation of bupivacaine enantiomers in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869373/),[ng] / [ml],15,37668,DB01075,Diphenhydramine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.0,42982,DB01075,Diphenhydramine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,5.5,42983,DB01075,Diphenhydramine
,24633923,"Cp,u","Oxycodone and diphenhydramine have CISF :Cp,u of 3.0 and 5.5, respectively, while CE-157119 has an unbound brain compound concentration (Cb,u ):Cp,u of 3.90; Cb,u is a high-confidence CISF surrogate.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42984,DB01075,Diphenhydramine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.61,42985,DB01075,Diphenhydramine
,24633923,"Cb,u :Cp,u","However, only CE-157119 has published dog and nonhuman primate (nhp) neuropharmacokinetics, which show similar Cb,u :Cp,u (4.61 and 2.04, respectively) as rats.",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,2.04,42986,DB01075,Diphenhydramine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,3.90,42987,DB01075,Diphenhydramine
,24633923,"Cb,u :Cp,u","The single-dose-derived rat Cb,u :Cp,u (3.90) was consistent with prior steady-state-derived CISF :Cp,u and similar to those in dogs (4.88) and nhp (4.51-5.00).",Diphenhydramine has similar interspecies net active influx at the blood-brain barrier. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24633923/),,4.88,42988,DB01075,Diphenhydramine
,17452029,flow rate,"Reverse-phase HPLC separation was accomplished on a Zorbax SB-C18 column (100 mm x 3.0 mm, 3.5 microm) with a mobile phase composed of methanol-water-formic acid (65:35:0.5, v/v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),[ml] / [min],0.2,43873,DB01075,Diphenhydramine
,17452029,total run time,The method had a chromatographic total run time of 5 min.,Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),min,5,43874,DB01075,Diphenhydramine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,136.0,43875,DB01075,Diphenhydramine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,91.0,43876,DB01075,Diphenhydramine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,256.0,43877,DB01075,Diphenhydramine
,17452029,m/,"A Varian 1200 L electrospray tandem mass spectrometer equipped with an electrospray ionization source was operated in selected reaction monitoring (SRM) mode with the precursor-to-product ion transitions m/z 136.0-->91.0 (D-amphetamine), 256.0-->167.0 (diphenhydramine) and 166.1-->148.0 (IS) used for quantitation.",Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17452029/),,166.1,43878,DB01075,Diphenhydramine
,12584158,efflux ratio,"Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.",P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584158/),,1,47722,DB01075,Diphenhydramine
,11709329,MTD,The MTD of L-AMB was at least 15 mg/kg/day.,"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[mg] / [d·kg],15,49177,DB01075,Diphenhydramine
,11709329,maximum concentration of drug in plasma (C(max)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[μg] / [ml],76,49178,DB01075,Diphenhydramine
,11709329,maximum concentration of drug in plasma (C(max)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[μg] / [ml],120,49179,DB01075,Diphenhydramine
,11709329,maximum concentration of drug in plasma (C(max)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[μg] / [ml],116,49180,DB01075,Diphenhydramine
,11709329,maximum concentration of drug in plasma (C(max)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[μg] / [ml],105,49181,DB01075,Diphenhydramine
,11709329,area under the concentration-time curve at 24 h (AUC(24)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[h·μg] / [ml],692,49182,DB01075,Diphenhydramine
,11709329,area under the concentration-time curve at 24 h (AUC(24)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[h·μg] / [ml],"1,062",49183,DB01075,Diphenhydramine
,11709329,area under the concentration-time curve at 24 h (AUC(24)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[h·μg] / [ml],860,49184,DB01075,Diphenhydramine
,11709329,area under the concentration-time curve at 24 h (AUC(24)),"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[h·μg] / [ml],554,49185,DB01075,Diphenhydramine
,11709329,CL,"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[ml] / [h·kg],23,49186,DB01075,Diphenhydramine
,11709329,CL,"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[ml] / [h·kg],18,49187,DB01075,Diphenhydramine
,11709329,CL,"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[ml] / [h·kg],16,49188,DB01075,Diphenhydramine
,11709329,CL,"The maximum concentration of drug in plasma (C(max)) of L-AMB in the dosage cohorts of 7.5, 10.0, 12.5, and 15.0 mg/kg/day changed to 76, 120, 116, and 105 microg/ml, respectively, and the mean area under the concentration-time curve at 24 h (AUC(24)) changed to 692, 1,062, 860, and 554 microg x h/ml, respectively, while mean CL changed to 23, 18, 16, and 25 ml/h/kg, respectively.","Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11709329/),[ml] / [h·kg],25,49189,DB01075,Diphenhydramine
higher,24140449,recoveries,"The mean recoveries of 10-HCPT at three concentrations of 2.5, 100, 2000ng/mL were higher than 87.2%.",Development and application of a UPLC-MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24140449/),%,87.2,54215,DB01075,Diphenhydramine
,24140449,biological half-life,The biological half-life of conjugate was increased significantly from 10min to 3.15h and the bioavailability was 40 times higher than 10-HCPT injection.,Development and application of a UPLC-MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24140449/),min,10,54216,DB01075,Diphenhydramine
,24140449,biological half-life,The biological half-life of conjugate was increased significantly from 10min to 3.15h and the bioavailability was 40 times higher than 10-HCPT injection.,Development and application of a UPLC-MS/MS method for the pharmacokinetic study of 10-hydroxy camptothecin and hydroxyethyl starch conjugate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24140449/),h,3.15,54217,DB01075,Diphenhydramine
,33940025,Rs,"Completely separation of R- and S-DPZ (Rs = 2.8) within 12 min was implemented on Chiralpak AGP column (100 × 4.0 mm i.d., 5 μm) employing ammonium acetate (10 mM; pH 4.5) - methanol (90:10, v/v) as mobile phase.",Enantiomeric Separation of Dioxopromethazine and its Stereoselective Pharmacokinetics in Rats by HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33940025/),,2.8,54263,DB01075,Diphenhydramine
,33940025,m/z,"The transitions of m/z 317.2 → 86.1 and 256.2 → 167.1 werechosen for monitoring DPZ enantiomers and IS, respectively.",Enantiomeric Separation of Dioxopromethazine and its Stereoselective Pharmacokinetics in Rats by HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33940025/),,317.2,54264,DB01075,Diphenhydramine
,33940025,m/z,"The transitions of m/z 317.2 → 86.1 and 256.2 → 167.1 werechosen for monitoring DPZ enantiomers and IS, respectively.",Enantiomeric Separation of Dioxopromethazine and its Stereoselective Pharmacokinetics in Rats by HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33940025/),,86.1,54265,DB01075,Diphenhydramine
,33940025,m/z,"The transitions of m/z 317.2 → 86.1 and 256.2 → 167.1 werechosen for monitoring DPZ enantiomers and IS, respectively.",Enantiomeric Separation of Dioxopromethazine and its Stereoselective Pharmacokinetics in Rats by HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33940025/),,256.2,54266,DB01075,Diphenhydramine
,33940025,m/z,"The transitions of m/z 317.2 → 86.1 and 256.2 → 167.1 werechosen for monitoring DPZ enantiomers and IS, respectively.",Enantiomeric Separation of Dioxopromethazine and its Stereoselective Pharmacokinetics in Rats by HPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33940025/),,167.1,54267,DB01075,Diphenhydramine
,26037160,flow rate,The isocratic mobile phase was 0.025% trifluoroacetic acid (TFA dissolved in acetonitrile) and 20 mM ammonium acetate (94:6) at a flow rate of 0.25 mL/min and diphenhydramine used as internal standard.,A novel HPLC-MS/MS method for the simultaneous determination of astemizole and its major metabolite in dog or monkey plasma and application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037160/),[ml] / [min],0.25,56269,DB01075,Diphenhydramine
,21251889,total run time,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,9.0,59775,DB01075,Diphenhydramine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,4.8,59776,DB01075,Diphenhydramine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.5,59777,DB01075,Diphenhydramine
,21251889,elution,"The total run time was 9.0 min and the elution of SASP, SP and 5-ASA was at 4.8 min, 2.5 min and 2.0 min, respectively.",Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251889/),min,2.0,59778,DB01075,Diphenhydramine
,27488910,Km,"In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5 nmol s-1 g-1.",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),mM,2.99,60658,DB01075,Diphenhydramine
,27488910,Vmax,"In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5 nmol s-1 g-1.",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),[nM] / [g·s],179.5,60659,DB01075,Diphenhydramine
,27488910,brain uptake clearance (Clup,"[11C]Diphenhydramine radiometabolites were not detected in the brain 15 min after injection, allowing for the reliable calculation of [11C]diphenhydramine brain uptake clearance (Clup = 0.99 ± 0.18 mL min-1 cm-3).",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),[ml] / [(cm)^3·min],0.99,60660,DB01075,Diphenhydramine
,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,256.0,64109,DB01075,Diphenhydramine
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,167.0,64110,DB01075,Diphenhydramine
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,325.0,64111,DB01075,Diphenhydramine
>,17442639,m/z,"The selected reaction monitoring (SRM) was set using precursor ion and product ion combinations of m/z 256.0>167.0 and m/z 325.0>109.0 for I and II, respectively.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),,109.0,64112,DB01075,Diphenhydramine
,17442639,limit of quantification (LOQ),"The limit of quantification (LOQ) was 0.4 ng/mL, the dynamic range being 0.4-200 ng/mL.",Determination of dimenhydrinate in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a relative bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442639/),[ng] / [ml],0.4,64113,DB01075,Diphenhydramine
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB01075,Diphenhydramine
,17127027,retention time,"The retention time of internal standard and tiropramide were 5.6+/-0.2 and 8.3+/-0.3 min, respectively.",A simple sample preparation with HPLC-UV method for estimation of tiropramide from plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127027/),min,5.6,68545,DB01075,Diphenhydramine
,17127027,retention time,"The retention time of internal standard and tiropramide were 5.6+/-0.2 and 8.3+/-0.3 min, respectively.",A simple sample preparation with HPLC-UV method for estimation of tiropramide from plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127027/),min,8.3,68546,DB01075,Diphenhydramine
,17127027,recovery,The mean recovery was found to be 89%.,A simple sample preparation with HPLC-UV method for estimation of tiropramide from plasma: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127027/),%,89,68547,DB01075,Diphenhydramine
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],61,72041,DB01075,Diphenhydramine
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],53,72042,DB01075,Diphenhydramine
,3718600,Peak serum levels,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),[ng] / [ml],40,72043,DB01075,Diphenhydramine
,3718600,elimination half-lives,"Peak serum levels of 61 and 53 ng/ml, respectively, for the test preparations and 40 ng/ml for the reference preparation were reached after 2.0 to 2.5 h p.a.; elimination half-lives were between 4 and 6 h.",[Pharmacokinetics and bioavailability of diphenhydramine in man]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718600/),h,4 and 6,72044,DB01075,Diphenhydramine
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,0.32,72315,DB01075,Diphenhydramine
,2882837,half-lives,"Taxol disappearance from plasma was biphasic; half-lives of the first and second phases after a 275 mg/m2 dose were 0.32 and 8.6 h, respectively.",Phase I clinical and pharmacokinetic study of taxol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),h,8.6,72316,DB01075,Diphenhydramine
,2882837,apparent volume of distribution,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),[l] / [m2],55,72317,DB01075,Diphenhydramine
,2882837,peak plasma concentration,"The apparent volume of distribution was 55 liters/m2, and the peak plasma concentration with a dose of 275 mg/m2, which occurred immediately postinfusion, was approximately 8 microM.",Phase I clinical and pharmacokinetic study of taxol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882837/),μM,8,72318,DB01075,Diphenhydramine
,22936420,flow rate,"Plasma samples were processed and analyzed on a Phenomenex Luna 3 μ CN 100A column (150 mm×2.0 mm) eluted with the mobile phase consisting of methanol and 0.01 mol/L ammonium acetate water solution containing 0.1% formic acid (45:55, v/v) at a flow rate of 0.2 mL/min.",Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),[ml] / [min],0.2,82874,DB01075,Diphenhydramine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,91.82,82875,DB01075,Diphenhydramine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,98.46,82876,DB01075,Diphenhydramine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,90.77,82877,DB01075,Diphenhydramine
,22936420,recovery,The mean recovery were ranged 91.82% ~ 98.46% for acrivastine and 90.77% ~ 92.05% for pseudoephedrine.,Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of acrivastine and pseudoephedrine in human plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936420/),%,92.05,82878,DB01075,Diphenhydramine
,33880775,flow rate,"After extraction, the prepared samples were run on an Agilent Welchrom C18 column with the mobile phase consisting of methanol-acetonitrile-water solution with 0.5% formic acid (45:50:5, v/v/v) at a flow rate of 0.8 mL·min-1 .",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),[ml] / [min],0.8,83292,DB01075,Diphenhydramine
,33880775,m/,"The analytes BBR, irbesartan, and diphenhydramine (IS) were detected using multiple reactions monitoring mode, with the ion transitions being m/z 336.1 → m/z 320.0, m/z 429.1 → m/z 206.9, and m/z 256.2 → m/z 167.0, respectively.",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),,429.1,83293,DB01075,Diphenhydramine
,33880775,m/z,"The analytes BBR, irbesartan, and diphenhydramine (IS) were detected using multiple reactions monitoring mode, with the ion transitions being m/z 336.1 → m/z 320.0, m/z 429.1 → m/z 206.9, and m/z 256.2 → m/z 167.0, respectively.",A rapid LC-MS/MS method for simultaneous determination of berberine and irbesartan in rat plasma: Application to the drug-drug pharmacokinetic interaction study after oral administration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33880775/),,256.2,83294,DB01075,Diphenhydramine
,8558221,overall response proportion,"The overall response proportion (CRs plus PRs) was 54% (95% confidence interval, 37% to 71%).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),%,54,92272,DB01075,Diphenhydramine
,8558221,time to response,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,12,92273,DB01075,Diphenhydramine
,8558221,duration,"The median time to response was 12 weeks (range, 3 to 15) and the median duration was 26 weeks (range, 10 to 58+).",Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8558221/),weeks,26,92274,DB01075,Diphenhydramine
,15018802,total run time,The method has a chromatographic total run time of 3.4 min and was linear within the range 2-2000 ng/ml.,Rapid determination of metformin in human plasma by liquid chromatography-tandem mass spectrometry method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018802/),min,3.4,95814,DB01075,Diphenhydramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.34,96056,DB01075,Diphenhydramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.40 to 0.60,96057,DB01075,Diphenhydramine
,2866055,Bioavailability,"Bioavailability has not been extensively studied, but is about 0.34 for chlorpheniramine, 0.40 to 0.60 for diphenhydramine, and about 0.25 for promethazine.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),,0.25,96058,DB01075,Diphenhydramine
,2866055,Total body clearance,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[ml] / [kg·min],5 to 12,96059,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,3,96060,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18,96061,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,4,96062,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,10 to 14,96063,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,14 to 25,96064,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,20,96065,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,25,96066,DB01075,Diphenhydramine
,2866055,elimination half-lives,"Total body clearance in adults is generally in the range of 5 to 12 ml/min/kg (for astemizole, brompheniramine, chlorpheniramine, diphenhydramine, hydroxyzine, promethazine and triprolidine), while their elimination half-lives range from about 3 hours to about 18 days [cinnarizine about 3 hours; diphenhydramine about 4 hours; promethazine 10 to 14 hours; chlorpheniramine 14 to 25 hours; hydroxyzine about 20 hours; brompheniramine about 25 hours; astemizole and its active metabolites about 7 to 20 days (after long term administration); flunarizine about 18 to 20 days].",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),d,18 to 20,96067,DB01075,Diphenhydramine
excess,2866055,apparent volumes of distribution,They also have relatively large apparent volumes of distribution in excess of 4 L/kg.,Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),[l] / [kg],4,96068,DB01075,Diphenhydramine
,2866055,elimination half-life,"In patients with alcohol-related liver disease, the elimination half-life of diphenhydramine was increased from 9 to 15 hours, while in patients with chronic renal disease that of chlorpheniramine was very greatly prolonged.",Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2866055/),h,9 to 15,96069,DB01075,Diphenhydramine
,26813802,Clarea,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),[ml] / [kg·min],20.7,96354,DB01075,Diphenhydramine
,26813802,Vdarea,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),[l] / [kg],7.6,96355,DB01075,Diphenhydramine
,26813802,T1/2,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),h,4.2,96356,DB01075,Diphenhydramine
,26813802,Clarea /F,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),[ml] / [kg·min],20.8,96357,DB01075,Diphenhydramine
,26813802,Vdarea /F,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),[l] / [kg],12.3,96358,DB01075,Diphenhydramine
,26813802,T1/2,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),[ml] / [kg·min],20.8,96359,DB01075,Diphenhydramine
,26813802,T1/2,"Diphenhydramine Clarea , Vdarea and T1/2 were 20.7 ± 2.9 mL/kg/min, 7.6 ± 0.7 L/kg and 4.2 ± 0.5 h for the i.v. route, respectively, and Clarea /F, Vdarea /F and T1/2 20.8 ± 2.7 mL/kg/min, 12.3 ± 1.2 L/kg and 6.8 ± 0.7 h for the i.m. route, respectively.",The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),h,6.8,96360,DB01075,Diphenhydramine
,26813802,Bioavailability,Bioavailability was 88% after i.m. administration.,The pharmacokinetics of DPH after the administration of a single intravenous or intramuscular dose in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813802/),%,88,96361,DB01075,Diphenhydramine
,23348611,flow rate,"The separation was performed on an Agilent ZORBAX Eclipse XDB-C(18) column (150mm×4.6mm, i.d., 5μm) at a flow rate of 0.6mL/min, and the mixture of methanol-water containing 0.1% formic acid was used as the mobile phase.",Simultaneous determination and pharmacokinetic study of stachydrine and leonurine in rat plasma after oral administration of Herba Leonuri extract by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23348611/),[ml] / [min],0.6,98470,DB01075,Diphenhydramine
,23348611,C(max),"After single oral administration of 14.5g/kg Herba Leonuri extract, C(max) of stachydrine and leonurine in rat plasma were respectively 1608±267 and 43.3±8.2ng/mL, while T(max) values were respectively 0.75±0.27 and 0.83±0.26h.",Simultaneous determination and pharmacokinetic study of stachydrine and leonurine in rat plasma after oral administration of Herba Leonuri extract by LC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23348611/),[ng] / [ml],1608,98471,DB01075,Diphenhydramine
,23348611,C(max),"After single oral administration of 14.5g/kg Herba Leonuri extract, C(max) of stachydrine and leonurine in rat plasma were respectively 1608±267 and 43.3±8.2ng/mL, while T(max) values were respectively 0.75±0.27 and 0.83±0.26h.",Simultaneous determination and pharmacokinetic study of stachydrine and leonurine in rat plasma after oral administration of Herba Leonuri extract by LC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23348611/),[ng] / [ml],43.3,98472,DB01075,Diphenhydramine
,23348611,T(max),"After single oral administration of 14.5g/kg Herba Leonuri extract, C(max) of stachydrine and leonurine in rat plasma were respectively 1608±267 and 43.3±8.2ng/mL, while T(max) values were respectively 0.75±0.27 and 0.83±0.26h.",Simultaneous determination and pharmacokinetic study of stachydrine and leonurine in rat plasma after oral administration of Herba Leonuri extract by LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23348611/),h,0.75,98473,DB01075,Diphenhydramine
,23348611,T(max),"After single oral administration of 14.5g/kg Herba Leonuri extract, C(max) of stachydrine and leonurine in rat plasma were respectively 1608±267 and 43.3±8.2ng/mL, while T(max) values were respectively 0.75±0.27 and 0.83±0.26h.",Simultaneous determination and pharmacokinetic study of stachydrine and leonurine in rat plasma after oral administration of Herba Leonuri extract by LC-MS/MS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23348611/),h,0.83,98474,DB01075,Diphenhydramine
,8622015,response duration,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,8.1,100300,DB01075,Diphenhydramine
,8622015,survival time,"The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients.",Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622015/),month,12.1,100301,DB01075,Diphenhydramine
,25375249,run time,"Detection was performed using an AB Sciex API 3000 triple quadrupole mass spectrometer, equipped with a Turbo Ion Spray source, operating in a positive mode: LEV at transition 171.1>154.1, UCB L057 at 172.5>126.1, and IS at 256.3>167.3; with an assay run time of 2 minutes.",Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),min,2,105617,DB01075,Diphenhydramine
,25375249,recoveries,Matrix effects were consistent between sources of plasma and the recoveries of all compounds were between 100% and 110%.,Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),%,100,105618,DB01075,Diphenhydramine
,25375249,recoveries,Matrix effects were consistent between sources of plasma and the recoveries of all compounds were between 100% and 110%.,Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25375249/),%,110,105619,DB01075,Diphenhydramine
,10824625,inhibitory constant,"In vitro, diphenhydramine was a potent competitive inhibitor of metoprolol alpha-hydroxylation, exhibiting an inhibitory constant of 2 micromol/L and increasing the Michaelis-Menten constant of metoprolol sixfold.",Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10824625/),[μM] / [l],2,105802,DB01075,Diphenhydramine
,8996529,renal,"The mean +/- SE renal and nonrenal clearances of hydroxyurea were 2.14 +/- 0.18 and 3.39 +/- 0.28 l/h per m2 (n = 16), neither of which correlated with the dose.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),[l] / [h·m2],2.14,108709,DB01075,Diphenhydramine
,8996529,nonrenal clearances,"The mean +/- SE renal and nonrenal clearances of hydroxyurea were 2.14 +/- 0.18 and 3.39 +/- 0.28 l/h per m2 (n = 16), neither of which correlated with the dose.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),[l] / [h·m2],3.39,108710,DB01075,Diphenhydramine
,8996529,half-life,The concentration of hydroxyurea in plasma decayed monoexponentially with a mean +/- SE half-life of 3.25 +/- 0.18 h (n = 17).,Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),h,3.25,108711,DB01075,Diphenhydramine
>,8996529,steady-state concentration,"The steady-state concentration of hydroxyurea was > 200 microM in all nine patients treated at 2 g/m2 per day, a dose which was well tolerated for 5 days.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),μM,200,108712,DB01075,Diphenhydramine
,16280265,m/,Selected ion monitoring (SIM) in positive mode was used for analyte quantification at m/z 480.2 for nicardipine and m/z 256.4 for diphenhydramine.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),,480.2,109486,DB01075,Diphenhydramine
less,16280265,run time,The run time was less than 5 min.,Liquid chromatography-mass spectrometry method for the determination of nicardipine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280265/),min,5,109487,DB01075,Diphenhydramine
,25272856,flow rate,"Agilent ZOBAX SB-C18 column (2.1 mm x 50 mm, 1.8 microm) was adopted and eluted with methanol and 0.1% formic acid (55:45), and the flow rate was 0.2 mL x min(-1).",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),[ml] / [min],0.2,109988,DB01075,Diphenhydramine
,25272856,signal to noise ratio S/N,"The target blood quality concentration show good linear relations within the range of 10.5-3 150 microg x L(-1) (R2 = 0.996), the lower limit of the standard curve was 10.5 microg x L(-1), and the signal to noise ratio S/N = 12.",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),,12,109989,DB01075,Diphenhydramine
,25272856,extraction recoveries,"Intra- and inter-day precisions RSD was less than 6.9% and 14%, respectively; The accuracy RE ranged between 0.20% and 3.7%; The extraction recoveries ranged between 92.7% and 97.1%.",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),%,92.7,109990,DB01075,Diphenhydramine
,25272856,extraction recoveries,"Intra- and inter-day precisions RSD was less than 6.9% and 14%, respectively; The accuracy RE ranged between 0.20% and 3.7%; The extraction recoveries ranged between 92.7% and 97.1%.",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),%,97.1,109991,DB01075,Diphenhydramine
,25272856,AUC (0-t),"Regarding the pharmacokinetic parameters of tail intravenous injection of cucurbitacin, AUC (0-t) was (811.615 +/- 111.578) microg x h x L(-1), (t1/2) was (1.285 +/- 1.390) h, CL was (3.627 +/- 0.487) L x h x kg(-1), and V(d) was (6.721 +/- 7.429) L x kg(-1).",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),[h·μg] / [l],811.615,109992,DB01075,Diphenhydramine
,25272856,t1/2),"Regarding the pharmacokinetic parameters of tail intravenous injection of cucurbitacin, AUC (0-t) was (811.615 +/- 111.578) microg x h x L(-1), (t1/2) was (1.285 +/- 1.390) h, CL was (3.627 +/- 0.487) L x h x kg(-1), and V(d) was (6.721 +/- 7.429) L x kg(-1).",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),h,1.285,109993,DB01075,Diphenhydramine
,25272856,CL,"Regarding the pharmacokinetic parameters of tail intravenous injection of cucurbitacin, AUC (0-t) was (811.615 +/- 111.578) microg x h x L(-1), (t1/2) was (1.285 +/- 1.390) h, CL was (3.627 +/- 0.487) L x h x kg(-1), and V(d) was (6.721 +/- 7.429) L x kg(-1).",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),[h·l] / [kg],3.627,109994,DB01075,Diphenhydramine
,25272856,V(d),"Regarding the pharmacokinetic parameters of tail intravenous injection of cucurbitacin, AUC (0-t) was (811.615 +/- 111.578) microg x h x L(-1), (t1/2) was (1.285 +/- 1.390) h, CL was (3.627 +/- 0.487) L x h x kg(-1), and V(d) was (6.721 +/- 7.429) L x kg(-1).",[Study on in vivo pharmacokinetics of cucurbitacin injection in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25272856/),[l] / [kg],6.721,109995,DB01075,Diphenhydramine
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB01075,Diphenhydramine
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB01075,Diphenhydramine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"76,600",127603,DB01075,Diphenhydramine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"90,600",127604,DB01075,Diphenhydramine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],525,127605,DB01075,Diphenhydramine
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],648,127606,DB01075,Diphenhydramine
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,544,127607,DB01075,Diphenhydramine
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,677,127608,DB01075,Diphenhydramine
,33765511,run time,The plasma samples were pretreated by a fast protein precipitation and chromatographed using a 1.7-μm C18 column and 0.1 % formic acid-water and acetonitrile via gradient elution with a run time of 3.7 min.,Rapid determination of seven bioactive components in rat plasma by UPLC-MS/MS and its application to pharmacokinetic compatibility study of Jinlingzi San. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33765511/),min,3.7,131463,DB01075,Diphenhydramine
,24013191,flow rate,"Blood samples were pre-stabilized with a stabilizing agent and then plasma was obtained and subjected to solid phase extraction (SPE), and chromatographed on a Phenomenex Kinetex(®) XB C18 column with gradient elution using a mobile phase consisting of acetonitrile-water (containing 0.1% formic acid and 1mM ammonium acetate) at a flow rate of 0.2mL/min for 3min.","A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),[ml] / [min],0.2,134255,DB01075,Diphenhydramine
,24013191,extraction recovery,The extraction recovery of disulfiram for different concentrations ranged from 75.7% to 78.3%.,"A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),%,75.7,134256,DB01075,Diphenhydramine
,24013191,extraction recovery,The extraction recovery of disulfiram for different concentrations ranged from 75.7% to 78.3%.,"A novel UPLC-ESI-MS/MS method for the quantitation of disulfiram, its role in stabilized plasma and its application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24013191/),%,78.3,134257,DB01075,Diphenhydramine
,9816021,maximum tolerated dose,The maximum tolerated dose of paclitaxel by a 3-h infusion was determined to be 240 mg/m2.,Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816021/),[mg] / [m],240,136639,DB01075,Diphenhydramine
,7398190,VD,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),[1] / [70],480,138461,DB01075,Diphenhydramine
,7398190,VD,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),kg,292,138462,DB01075,Diphenhydramine
,7398190,Cl,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),[1] / [70·h·kg],79,138463,DB01075,Diphenhydramine
,7398190,Cl,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),[1] / [70·h·kg],51,138464,DB01075,Diphenhydramine
,7398190,t 1/2,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),h,4.1,138465,DB01075,Diphenhydramine
,7398190,t 1/2,"With the assumption of linear kinetics and a 1-compartment open model, analysis of the data showed that the volume of distribution (VD) and plasma clearance (Cl) but not plasma half-life (t 1/2) were higher in Orientals than Caucasians: [VD = 480 +/- 24 (SEM) and 292 +/- 36 1/70 kg; Cl = 79 +/- 7 and 51 +/- 7 1/70 kg/hr; t 1/2 = 4.1 +/- 0.4 and 4.3 +/- 0.4 hr].",Diphenhydramine in Orientals and Caucasians. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7398190/),h,4.3,138466,DB01075,Diphenhydramine
,22691110,area under the curve concentration,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[h·ng] / [ml],20.1,141529,DB01075,Diphenhydramine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[h·ng] / [ml],23.7,141530,DB01075,Diphenhydramine
,22691110,maximum concentration reached,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),,7.7,141531,DB01075,Diphenhydramine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[ng] / [ml],11.0,141532,DB01075,Diphenhydramine
,22691110,time to reach maximum concentration,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),,0.25,141533,DB01075,Diphenhydramine
,22691110,AUTO,"Pharmacokinetic results were as follows: area under the curve concentration, DPIA=20.1±5.8, AUTO=23.7±4.9 ng hr/mL (means±SD); maximum concentration reached, DPIA=7.7±3.5, AUTO=11.0±3.8 ng/mL; time to reach maximum concentration, DPIA=0.25±0.47, AUTO=0.19±0.23 hr.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),h,0.19,141534,DB01075,Diphenhydramine
,22691110,AUTO,"Pharmacodynamic results were as follows: maximum increase in heart rate, DPIA=18±12, AUTO=23±13 beats/min; average change in 1-sec forced expiratory volume at 30 min, DPIA=0.16±0.22 L, AUTO=0.11±0.29 L.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),[beats] / [min],23,141535,DB01075,Diphenhydramine
,22691110,AUTO,"Pharmacodynamic results were as follows: maximum increase in heart rate, DPIA=18±12, AUTO=23±13 beats/min; average change in 1-sec forced expiratory volume at 30 min, DPIA=0.16±0.22 L, AUTO=0.11±0.29 L.",Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),l,0.11,141536,DB01075,Diphenhydramine
,22691110,relative bioavailability,The relative bioavailability for DPIA was 87% (based on output dose).,Systemic delivery of atropine sulfate by the MicroDose Dry-Powder Inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22691110/),%,87,141537,DB01075,Diphenhydramine
,16413836,run time,The instrument parameters were optimized to obtain 3.0 min run time.,Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413836/),min,3.0,145075,DB01075,Diphenhydramine
,16413836,flow rate,"The mobile phase consisted of acetonitrile-water-formic acid (70:30:0.5), at a flow rate of 0.5 ml/min.",Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413836/),[ml] / [min],0.5,145076,DB01075,Diphenhydramine
,21472729,K(i),Oxycodone competitively inhibited DPHM uptake with a K(i) value of 106 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,106,145692,DB01075,Diphenhydramine
,21472729,K(i),DPHM also competitively inhibited oxycodone uptake with a K(i) value of 34.7 μM.,Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21472729/),μM,34.7,145693,DB01075,Diphenhydramine
,2109056,initial distribution half-life,The initial distribution half-life increased from 5 to 9 min and the elimination half-life from 34 to 68 min as the dose was increased.,Pharmacokinetics of diphenhydramine after dose ranging in nonpregnant ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109056/),min,5 to 9,150689,DB01075,Diphenhydramine
,2109056,elimination half-life,The initial distribution half-life increased from 5 to 9 min and the elimination half-life from 34 to 68 min as the dose was increased.,Pharmacokinetics of diphenhydramine after dose ranging in nonpregnant ewes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109056/),min,34 to 68,150690,DB01075,Diphenhydramine
,2109056,volume of distribution,There was also an increase in the volume of distribution (from 3 to 6 L/kg) with increasing dose.,Pharmacokinetics of diphenhydramine after dose ranging in nonpregnant ewes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109056/),[l] / [kg],3,150691,DB01075,Diphenhydramine
,2109056,total body clearance,The average total body clearance (approximately 5 L/h/kg) remained unchanged regardless of dose.,Pharmacokinetics of diphenhydramine after dose ranging in nonpregnant ewes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109056/),[l] / [h·kg],5,150692,DB01075,Diphenhydramine
,2109056,free fraction,"The free fraction of diphenhydramine determined by equilibrium dialysis averaged 0.229 +/- 0.080, and the extent of drug binding to plasma protein was independent of the drug concentrations encountered (30-780 ng/mL) in the nonpregnant sheep in vivo.",Pharmacokinetics of diphenhydramine after dose ranging in nonpregnant ewes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109056/),,0.229,150693,DB01075,Diphenhydramine
,2328304,peak plasma concentrations,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[ng] / [ml],38.3,154753,DB01075,Diphenhydramine
,2328304,peak plasma concentrations,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[ng] / [ml],47.8,154754,DB01075,Diphenhydramine
,2328304,time of peak concentration,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),h,2.6,154755,DB01075,Diphenhydramine
,2328304,time of peak concentration,"Mean peak plasma concentrations after sublingual administration were slightly lower than after oral dosage (38.3 vs 47.8 ng ml-1), and the time of peak concentration was similar (2.6 vs 2.3 h after dose).","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),h,2.3,154756,DB01075,Diphenhydramine
,2328304,total area under the plasma concentration-time curve (AUC),The mean total area under the plasma concentration-time curve (AUC) for sublingual administration was slightly but not significantly smaller than after oral dosage (221 vs 270 h ng ml-1).,"Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[h·ng] / [ml],221,154757,DB01075,Diphenhydramine
,2328304,total area under the plasma concentration-time curve (AUC),The mean total area under the plasma concentration-time curve (AUC) for sublingual administration was slightly but not significantly smaller than after oral dosage (221 vs 270 h ng ml-1).,"Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),[h·ng] / [ml],270,154758,DB01075,Diphenhydramine
,2328304,Systemic availability,"Systemic availability of diphenhydramine after sublingual dimenhydrinate, measured by the ratio of oral AUC to intravenous AUC, was slightly less than after oral dimenhydrinate (0.58 vs 0.69, NS), and both were significantly less than 1.0.","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),,0.58,154759,DB01075,Diphenhydramine
,2328304,Systemic availability,"Systemic availability of diphenhydramine after sublingual dimenhydrinate, measured by the ratio of oral AUC to intravenous AUC, was slightly less than after oral dimenhydrinate (0.58 vs 0.69, NS), and both were significantly less than 1.0.","Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328304/),,0.69,154760,DB01075,Diphenhydramine
,28967696,Tmax,"Over an 8-fold range of doses, Cmax and AUC increased ∼90 % to ∼140% across age groups, with a similar Tmax (1.5 hours).",Single-Dose Pharmacokinetic Study of Diphenhydramine HCl in Children and Adolescents. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967696/),h,1.5,156054,DB01075,Diphenhydramine
,19217739,flow rate,"After a simple sample preparation procedure involving a one-step liquid-liquid extraction, alprostadil and the internal standard, diphenhydramine, were chromatographed on an ACQUITY UPLC BEH C(18) column with gradient elution using a mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.25 mL min(-1).",Determination of alprostadil in rat plasma by ultra performance liquid chromatography-electrospray ionization-tandem mass spectrometry after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217739/),[ml] / [min],0.25,161894,DB01075,Diphenhydramine
,10101141,clearance,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[ml] / [kg·min],0.55,167553,DB01075,Diphenhydramine
,10101141,clearance,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[ml] / [kg·min],40.9,167554,DB01075,Diphenhydramine
,10101141,clearance,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[ml] / [kg·min],0.37,167555,DB01075,Diphenhydramine
,10101141,clearance,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[ml] / [kg·min],285. 6,167556,DB01075,Diphenhydramine
,10101141,steady-state volume of distribution (Vdss,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[l] / [kg],0.10,167557,DB01075,Diphenhydramine
,10101141,steady-state volume of distribution (Vdss,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[l] / [kg],2.1,167558,DB01075,Diphenhydramine
,10101141,steady-state volume of distribution (Vdss,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[l] / [kg],0.40,167559,DB01075,Diphenhydramine
,10101141,steady-state volume of distribution (Vdss,"The preformed DPMA (or [2H10]-DPMA) had a substantially lower clearance (maternal: 0.55 +/- 0.18 versus 40.9 +/- 14.0 ml/min/kg; fetal: 0.37 +/- 0.11 versus 285. 6 +/- 122.2 ml/min/kg) and steady-state volume of distribution (Vdss, maternal: 0.10 +/- 0.02 versus 2.1 +/- 1.1 l/kg; fetal: 0.40 +/- 0. 06 versus 13.1 +/- 3.1 l/kg) as compared with the parent drug.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),[l] / [kg],13.1,167560,DB01075,Diphenhydramine
,10101141,recoveries,"The recoveries of DPMA (or [2H10]-DPMA) in maternal urine were 88.0 +/- 6.5 and 92.1 +/- 7. 4% of the administered dose during maternal and fetal dosing experiments, respectively.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),%,88.0,167561,DB01075,Diphenhydramine
,10101141,recoveries,"The recoveries of DPMA (or [2H10]-DPMA) in maternal urine were 88.0 +/- 6.5 and 92.1 +/- 7. 4% of the administered dose during maternal and fetal dosing experiments, respectively.","Comparative formation, distribution, and elimination kinetics of diphenylmethoxyacetic acid (a diphenhydramine metabolite) in maternal and fetal sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10101141/),%,92.1,167562,DB01075,Diphenhydramine
,17016805,Maximum plasma concentration,Maximum plasma concentration was 12.3 +/- 2.73 ng/mL which occurred at 3.50 +/- 1.61 h post-dosing.,Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),[ng] / [ml],12.3,177544,DB01075,Diphenhydramine
,17016805,apparent elimination half-life,"The apparent elimination half-life and the area under the curve were, respectively, 60.86 +/- 12.05 h and 609.3 +/- 122.2 ng .",Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),h,60.86,177545,DB01075,Diphenhydramine
,17016805,area under the curve,"The apparent elimination half-life and the area under the curve were, respectively, 60.86 +/- 12.05 h and 609.3 +/- 122.2 ng .",Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),ng,609.3,177546,DB01075,Diphenhydramine
,8251550,m/z,The method employed electron impact ionization with selective ion monitoring of ions with m/z 165 for DPHM and m/z 173 for (2H10)DPHM.,Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10)diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251550/),,165,180902,DB01075,Diphenhydramine
,8251550,m/z,The method employed electron impact ionization with selective ion monitoring of ions with m/z 165 for DPHM and m/z 173 for (2H10)DPHM.,Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10)diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251550/),,173,180903,DB01075,Diphenhydramine
,8251550,minimal quantifiable concentration,"The minimal quantifiable concentration of DPHM and (2H10)DPHM from a 1.0 ml sample was 2.0 ng ml-1 in fetal and maternal plasma, fetal tracheal fluid and amniotic fluid.",Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10)diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251550/),[ng] / [ml],2.0,180904,DB01075,Diphenhydramine
,12851661,AUC(0-24h),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[h·ng] / [ml],155.2,182433,DB01075,Diphenhydramine
,12851661,AUC(0-infinity),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[h·ng] / [ml],195.3,182434,DB01075,Diphenhydramine
,12851661,resident time,Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,16,182435,DB01075,Diphenhydramine
,12851661,t(1/2),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,10,182436,DB01075,Diphenhydramine
,12851661,C(max),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[ng] / [ml],14.5,182437,DB01075,Diphenhydramine
,12851661,t(max),Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),h,2.6,182438,DB01075,Diphenhydramine
,12851661,plasma clearance,Analytical data revealed the following kinetic parameters: AUC(0-24h): 155.2h x ng x ml(-1); AUC(0-infinity): 195.3 h x ng x ml(-1); Mean resident time: 16 h; t(1/2): 10 h; C(max): 14.5 ng x ml(-1); t(max): 2.6 h; and plasma clearance: 9.0 ml x min(-1) x kg(-1).,Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 25 mg chewing gum formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851661/),[ml] / [kg·min],9.0,182439,DB01075,Diphenhydramine
,2391399,serum elimination half-life,"The mean serum elimination half-life values for diphenhydramine differed significantly in elderly adults, young adults, and children, with values of 13.5 +/- 4.2 hours, 9.2 +/- 2.5 hours, and 5.4 +/- 1.8 hours being found respectively in each age group.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),h,13.5,183409,DB01075,Diphenhydramine
,2391399,serum elimination half-life,"The mean serum elimination half-life values for diphenhydramine differed significantly in elderly adults, young adults, and children, with values of 13.5 +/- 4.2 hours, 9.2 +/- 2.5 hours, and 5.4 +/- 1.8 hours being found respectively in each age group.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),h,9.2,183410,DB01075,Diphenhydramine
,2391399,serum elimination half-life,"The mean serum elimination half-life values for diphenhydramine differed significantly in elderly adults, young adults, and children, with values of 13.5 +/- 4.2 hours, 9.2 +/- 2.5 hours, and 5.4 +/- 1.8 hours being found respectively in each age group.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),h,5.4,183411,DB01075,Diphenhydramine
,2391399,Clearance rates,"Clearance rates for diphenhydramine also differed significantly with age, being 11.7 +/- 3.1 mL/min/kg in elderly adults, 23.3 +/- 9.4 mL/min/kg in young adults and 49.2 +/- 22.8 mL/min/kg in children.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),[ml] / [kg·min],11.7,183412,DB01075,Diphenhydramine
,2391399,Clearance rates,"Clearance rates for diphenhydramine also differed significantly with age, being 11.7 +/- 3.1 mL/min/kg in elderly adults, 23.3 +/- 9.4 mL/min/kg in young adults and 49.2 +/- 22.8 mL/min/kg in children.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),[ml] / [kg·min],23.3,183413,DB01075,Diphenhydramine
,2391399,Clearance rates,"Clearance rates for diphenhydramine also differed significantly with age, being 11.7 +/- 3.1 mL/min/kg in elderly adults, 23.3 +/- 9.4 mL/min/kg in young adults and 49.2 +/- 22.8 mL/min/kg in children.","Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),[ml] / [kg·min],49.2,183414,DB01075,Diphenhydramine
,2391399,maximum wheal suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,39.6,183415,DB01075,Diphenhydramine
,2391399,maximum flare suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,46.5,183416,DB01075,Diphenhydramine
,2391399,maximum wheal suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,45.5,183417,DB01075,Diphenhydramine
,2391399,maximum flare suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,53.4,183418,DB01075,Diphenhydramine
,2391399,maximum wheal suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,68.4,183419,DB01075,Diphenhydramine
,2391399,maximum flare suppression,Diphenhydramine produced a maximum wheal suppression of 39.6 +/- 22.5% and a maximum flare suppression of 46.5 +/- 32.1% at 5 and 6 hours respectively in the elderly; a maximum wheal suppression of 45.5 +/- 25.0% and a maximum flare suppression of 53.4 +/- 16.9% at 6 and 4 hours respectively in young adults; and a maximum wheal suppression of 68.4 +/- 10.2% and a maximum flare suppression of 87.2 +/- 4.2% at 2 hours in children.,"Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391399/),%,87.2,183420,DB01075,Diphenhydramine
,15692141,maximum APAP concentration ([APAP](max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg] / [ml],71.8,186083,DB01075,Diphenhydramine
,15692141,time to peak [APAP] (t(max)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.71,186084,DB01075,Diphenhydramine
,15692141,area under the receiver operating characteristic curve (AUC(0-8)),"For APAP alone, the mean parameters were: maximum APAP concentration ([APAP](max)) 71.8 microg/mL, time to peak [APAP] (t(max)) 1.71 hours, and area under the receiver operating characteristic curve (AUC(0-8)) 318.3 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],318.3,186085,DB01075,Diphenhydramine
,15692141,t(max),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,1.90,186086,DB01075,Diphenhydramine
,15692141,AUC(0-8),"For APAP+DPH, the mean parameters were: [APAP](max) 67.6 microg/mL, t(max) 1.90 hours, and AUC(0-8) 297.7 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],297.7,186087,DB01075,Diphenhydramine
,15692141,t(max),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),h,2.87,186088,DB01075,Diphenhydramine
,15692141,AUC(0-8),"For APAP+OXY, the parameters were: [APAP](max) 42.9 microg/mL, t(max) 2.87 hours, and AUC(0-8) 232.1 microg-hr/mL.",Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692141/),[μg-hr] / [ml],232.1,186089,DB01075,Diphenhydramine
,8096848,flow-rate,"A mobile phase of methanol-0.02 M acetate buffer (pH 4.7) (25:75,v/v) at a flow-rate of 1.0 ml/min was used for the urine assays.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),[ml] / [min],1.0,188915,DB01075,Diphenhydramine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,15,188916,DB01075,Diphenhydramine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,25,188917,DB01075,Diphenhydramine
,8096848,retention times,"(+)-HCZ, (-)-HCZ and the internal standard were eluted at retention times of 15, 25 and 8 min, respectively.",Enantioselective pharmacokinetics of homochlorcyclizine. Simultaneous determination of (+)- and (-)- homochlorcyclizine in human urine by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8096848/),min,8,188918,DB01075,Diphenhydramine
,30779257,systemic availabilities,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),%,7.8,190950,DB01075,Diphenhydramine
,30779257,systemic availabilities,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),%,22.0,190951,DB01075,Diphenhydramine
,30779257,maximum concentrations,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),[ng] / [ml],36,190952,DB01075,Diphenhydramine
,30779257,maximum concentrations,"The mean systemic availabilities of diphenhydramine were 7.8% and 22.0% after oral administration of diphenhydramine and dimenhydrinate, respectively, whereas the mean maximum concentrations were 36 (± 20) and 124 (± 46) ng/mL.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),[ng] / [ml],124,190953,DB01075,Diphenhydramine
,30779257,terminal elimination half-lives,"The terminal elimination half-lives of diphenhydramine and dimenhydrinate were 5.0 (± 7.1) and 11.6 (± 17.7) h, respectively.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),h,5.0,190954,DB01075,Diphenhydramine
,30779257,terminal elimination half-lives,"The terminal elimination half-lives of diphenhydramine and dimenhydrinate were 5.0 (± 7.1) and 11.6 (± 17.7) h, respectively.","Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30779257/),h,11.6,190955,DB01075,Diphenhydramine
more,23328074,maximum tolerated dose (MTD),A pediatric study has established a maximum tolerated dose (MTD) for temsirolimus (Tem) of more than 150 mg/m intravenously/week.,Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328074/),[mg] / [m],150,194972,DB01075,Diphenhydramine
,16202668,limit of detection,The assay was linear over the range 0.5-600.0 ng/ml with a limit of quantitation of 0.5 ng/ml and a limit of detection of 0.05 ng/ml.,Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16202668/),[ng] / [ml],0.05,195049,DB01075,Diphenhydramine
,11839657,central volume of distribution,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[l] / [m(2],1.45,195160,DB01075,Diphenhydramine
,11839657,clearance,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),[h·l] / [m(2],0.03,195161,DB01075,Diphenhydramine
,11839657,elimination half-life,"Mean estimates of central volume of distribution, clearance, and elimination half-life were 1.45 liters/m(2), 0.03 liter/h/m(2), and 36.4 h, respectively.",Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839657/),h,36.4,195162,DB01075,Diphenhydramine
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,21,195947,DB01075,Diphenhydramine
,9816254,response rates,"Paclitaxel has clinical activity in non-small cell lung cancer, with response rates of 21 and 24% in a 24-h infusion.",Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816254/),%,24,195948,DB01075,Diphenhydramine
,11304721,T(max),"Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.3,196206,DB01075,Diphenhydramine
,11304721,"t(1/2,z)","Significant treatment differences seen for naproxen T(max) (0.3 h, males only) and diphenhydramine t(1/2,z) (0.8 h, females only) were minor and are unlikely to have therapeutic consequences.",Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304721/),h,0.8,196207,DB01075,Diphenhydramine
,20570577,flow rate,"Following protein precipitation by methanol, the analytes were separated on an ACQUITY UPLC BEH C(18) column packed with 1.7 microm particles by gradient elution using a mobile phase composed of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.20 mL/min.","Simultaneous determination of vitexin-4''-O-glucoside, vitexin-2''-O-rhamnoside, rutin and vitexin from hawthorn leaves flavonoids in rat plasma by UPLC-ESI-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570577/),[ml] / [min],0.20,199020,DB01075,Diphenhydramine
,20570577,m,"The analytes and diphenhydramine (internal standard, IS) were detected in the multiple reaction monitoring (MRM) mode by means of an electrospray ionization (ESI) interface (m/z 292.96 for vitexin-4''-O-glucoside, m/z 293.10 for vitexin-2''-O-rhamnoside, m/z 299.92 for rutin, m/z 310.94 for vitexin and m/z 166.96 for IS).","Simultaneous determination of vitexin-4''-O-glucoside, vitexin-2''-O-rhamnoside, rutin and vitexin from hawthorn leaves flavonoids in rat plasma by UPLC-ESI-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570577/),,293.10,199021,DB01075,Diphenhydramine
,20570577,m/,"The analytes and diphenhydramine (internal standard, IS) were detected in the multiple reaction monitoring (MRM) mode by means of an electrospray ionization (ESI) interface (m/z 292.96 for vitexin-4''-O-glucoside, m/z 293.10 for vitexin-2''-O-rhamnoside, m/z 299.92 for rutin, m/z 310.94 for vitexin and m/z 166.96 for IS).","Simultaneous determination of vitexin-4''-O-glucoside, vitexin-2''-O-rhamnoside, rutin and vitexin from hawthorn leaves flavonoids in rat plasma by UPLC-ESI-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570577/),,299.92,199022,DB01075,Diphenhydramine
,20570577,m/,"The analytes and diphenhydramine (internal standard, IS) were detected in the multiple reaction monitoring (MRM) mode by means of an electrospray ionization (ESI) interface (m/z 292.96 for vitexin-4''-O-glucoside, m/z 293.10 for vitexin-2''-O-rhamnoside, m/z 299.92 for rutin, m/z 310.94 for vitexin and m/z 166.96 for IS).","Simultaneous determination of vitexin-4''-O-glucoside, vitexin-2''-O-rhamnoside, rutin and vitexin from hawthorn leaves flavonoids in rat plasma by UPLC-ESI-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570577/),,310.94,199023,DB01075,Diphenhydramine
,22923967,mass-to-charge ratio (m/z),"The ions chosen were of a mass-to-charge ratio (m/z) exactly equal to 44 units, in order to measure fluoxetine enantiomers, 134 units in order to measure norfluoxetine enantiomers, and 58 units in order to measure diphenhydramine, the internal standard.",A novel chiral GC/MS method for the analysis of fluoxetine and norfluoxetine enantiomers in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22923967/),units,44,199689,DB01075,Diphenhydramine
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,9.1,202531,DB01075,Diphenhydramine
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,10.0,202532,DB01075,Diphenhydramine
,7704215,m/,"One ion was monitored for each compound, namely, m/z 165 for the internal standard diphenylacetic acid, m/z 183 for DPMA, and m/z 177 for [2H10]DPMA.","Simultaneous analysis of diphenylmethoxyacetic acid, a metabolite of diphenhydramine, and its deuterium-labeled stable isotope analog in ovine plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704215/),,165,204014,DB01075,Diphenhydramine
,7704215,m/z,"One ion was monitored for each compound, namely, m/z 165 for the internal standard diphenylacetic acid, m/z 183 for DPMA, and m/z 177 for [2H10]DPMA.","Simultaneous analysis of diphenylmethoxyacetic acid, a metabolite of diphenhydramine, and its deuterium-labeled stable isotope analog in ovine plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7704215/),,183,204015,DB01075,Diphenhydramine
,9918600,IC50,"Finally, experiments performed with the patch-clamp technique demonstrated unequivocal block of the rapid component of the delayed rectifier (IKr) by DPH; however, IC50 determined for block of IKr (3 x 10(-5) M) is approximately 40-fold greater than plasma concentrations of the drug measured at usual dosages (7 x 10(-7) M).",Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918600/),M,3 x 10(-5),204696,DB01075,Diphenhydramine
,9918600,IC50,"Finally, experiments performed with the patch-clamp technique demonstrated unequivocal block of the rapid component of the delayed rectifier (IKr) by DPH; however, IC50 determined for block of IKr (3 x 10(-5) M) is approximately 40-fold greater than plasma concentrations of the drug measured at usual dosages (7 x 10(-7) M).",Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918600/),,7,204697,DB01075,Diphenhydramine
,26142429,flow rate,"The analytes and internal standard diphenhydramine were separated on a Zorbax SB-C18 column with a mobile phase of acetonitrile : water (45 : 55, v/v) at a flow rate of 0.2 mL/min with an operating temperature of 25°C.",Simultaneous determination of telmisartan and amlodipine in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26142429/),[ml] / [min],0.2,204922,DB01075,Diphenhydramine
>,26142429,recoveries,The average recoveries of analytes were >85.0%.,Simultaneous determination of telmisartan and amlodipine in dog plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26142429/),%,85.0,204923,DB01075,Diphenhydramine
,19200686,flow rate,"The mobile phase was methanol:water (80:20, v/v) containing 0.2% formic acid delivered at a flow rate of 0.5 mL/min.",Determination of tropisetron in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19200686/),[ml] / [min],0.5,210107,DB01075,Diphenhydramine
,19200686,total chromatographic run time,The total chromatographic run time was 4.5 min.,Determination of tropisetron in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19200686/),min,4.5,210108,DB01075,Diphenhydramine
,20430774,maximum-tolerated dose,The maximum-tolerated dose was 15 mg/m(2).,A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430774/),[mg] / [m],15,213036,DB01075,Diphenhydramine
,18291133,flow rate,"The analytes, bufalin, cinobufagin, resibufogenin and the internal standard, diphenhydramine were extracted from rat plasma samples by a one-step liquid-liquid extraction and separated on an ACQUITY UPLCtrade mark BEH C(18) column with gradient elution using a mobile phase composed of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.20 mL min(-1).",Simultaneous determination of three bufadienolides in rat plasma after intravenous administration of bufadienolides extract by ultra performance liquid chromatography electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18291133/),[ml] / [min],0.20,213922,DB01075,Diphenhydramine
,11393705,flow rate,"The mobile phase consisted of acetonitrile-water-formic acid (60:40:1, v/v/v), at a flow rate of 0.5 ml/min.",Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393705/),[ml] / [min],0.5,219522,DB01075,Diphenhydramine
,11393705,limit of,"The method has a limit of quantitation of 10 ng/ml for flupirtine and 2 ng/ml for D-13223, using 0.5-ml plasma sample.",Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393705/),[ng] / [ml],10,219523,DB01075,Diphenhydramine
,11393705,limit of,"The method has a limit of quantitation of 10 ng/ml for flupirtine and 2 ng/ml for D-13223, using 0.5-ml plasma sample.",Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393705/),[ng] / [ml],2,219524,DB01075,Diphenhydramine
,11393705,overall extraction recoveries,"The overall extraction recoveries of flupirtine and D-13223 were determined to be about 66% and 78% on average, respectively.",Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393705/),%,66,219525,DB01075,Diphenhydramine
,11393705,overall extraction recoveries,"The overall extraction recoveries of flupirtine and D-13223 were determined to be about 66% and 78% on average, respectively.",Simultaneous determination of flupirtine and its major active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393705/),%,78,219526,DB01075,Diphenhydramine
,4020379,elimination half-life,"Her elimination half-life for desipramine was found to be greatly prolonged, at approximately 150 hours.",Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020379/),h,150,220633,DB01075,Diphenhydramine
,12452753,elimination half-life,The elimination half-life of both drugs is 0.5-0.7 hours.,Fluorouracil for allergic reactions to capecitabine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12452753/),h,0.5-0.7,222981,DB01075,Diphenhydramine
,7944484,maximum tolerated dose,The maximum tolerated dose was 200 mg/m2.,[Phase I study of paclitaxel]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),[mg] / [m],200,224512,DB01075,Diphenhydramine
,7944484,half-life,The paclitaxel plasma concentration declined with a half-life of 10.0 to 24.9 hours.,[Phase I study of paclitaxel]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),h,10.0 to 24.9,224513,DB01075,Diphenhydramine
,7944484,Excretion into urine,Excretion into urine within 72 hours was in the range of 7.28 to 11.34% of paclitaxel dosage.,[Phase I study of paclitaxel]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944484/),%,7.28 to 11.34,224514,DB01075,Diphenhydramine
,3761171,apparent terminal elimination half-life,The average apparent terminal elimination half-life in the ewe (52 min) was not significantly different from that obtained in the fetus (46 min).,Placental transfer of diphenhydramine in chronically instrumented pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761171/),min,52,225966,DB01075,Diphenhydramine
,3761171,apparent terminal elimination half-life,The average apparent terminal elimination half-life in the ewe (52 min) was not significantly different from that obtained in the fetus (46 min).,Placental transfer of diphenhydramine in chronically instrumented pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761171/),min,46,225967,DB01075,Diphenhydramine
,3761171,total body clearance,"The maternal total body clearance was 3.6 L X h-1 X kg-1, and the volume of distribution at steady state was 3.2 L/kg.",Placental transfer of diphenhydramine in chronically instrumented pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761171/),[l] / [h·kg],3.6,225968,DB01075,Diphenhydramine
,3761171,volume of distribution at steady state,"The maternal total body clearance was 3.6 L X h-1 X kg-1, and the volume of distribution at steady state was 3.2 L/kg.",Placental transfer of diphenhydramine in chronically instrumented pregnant sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761171/),[l] / [kg],3.2,225969,DB01075,Diphenhydramine
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],103,233096,DB01075,Diphenhydramine
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],100,233097,DB01075,Diphenhydramine
,2723113,time of peak,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.40,233098,DB01075,Diphenhydramine
,2723113,time of peak,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,1.87,233099,DB01075,Diphenhydramine
,2723113,elimination half-life,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,10.1,233100,DB01075,Diphenhydramine
,2723113,elimination half-life,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,10.2,233101,DB01075,Diphenhydramine
,2723113,total clearance,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],3.70,233102,DB01075,Diphenhydramine
,2723113,total clearance,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],3.88,233103,DB01075,Diphenhydramine
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],63.7,233104,DB01075,Diphenhydramine
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],73.8,233105,DB01075,Diphenhydramine
,2723113,time of peak,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.7,233106,DB01075,Diphenhydramine
,2723113,time of peak,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.2,233107,DB01075,Diphenhydramine
,2723113,elimination half-life,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,6.0,233108,DB01075,Diphenhydramine
,2723113,elimination half-life,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,5.1,233109,DB01075,Diphenhydramine
,2723113,total clearance,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],21.8,233110,DB01075,Diphenhydramine
,2723113,total clearance,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],25.5,233111,DB01075,Diphenhydramine
,25480582,flow rate,"The two bioactive alkaloids were separated on a Zorbax SB-C18 reserved-phase column (150 mm × 4.6 mm, i.d., 5 μm) by gradient elution using a mobile phase consisting of methanol with 0.1% formic acid (A) and water with 0.1% formic acid (B) at a flow rate of 0.6 mL/min.",An LC-MS/MS method for the simultaneous determination of lycorine and galanthamine in rat plasma and its application to pharmacokinetic study of Lycoris radiata extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25480582/),[ml] / [min],0.6,237706,DB01075,Diphenhydramine
more,25480582,extraction recovery,"The average extraction recovery of the analytes from rat plasma was more than 82.15%, and the intra-day and inter-day accuracy and precision of the assay were less than 12.6%.",An LC-MS/MS method for the simultaneous determination of lycorine and galanthamine in rat plasma and its application to pharmacokinetic study of Lycoris radiata extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25480582/),%,82.15,237707,DB01075,Diphenhydramine
less,25480582,extraction recovery,"The average extraction recovery of the analytes from rat plasma was more than 82.15%, and the intra-day and inter-day accuracy and precision of the assay were less than 12.6%.",An LC-MS/MS method for the simultaneous determination of lycorine and galanthamine in rat plasma and its application to pharmacokinetic study of Lycoris radiata extract in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25480582/),%,12.6,237708,DB01075,Diphenhydramine
,16510542,steady-state CNS/total plasma concentration ratios,"Average steady-state CNS/total plasma concentration ratios (i.e., [CNS]/[total plasma]) for steps 1 to 5 ranged from 0.4 to 0.5.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),,0.4 to 0.5,240130,DB01075,Diphenhydramine
,16510542,steady-state [CNS]/[free plasma] ratios,"However, average steady-state [CNS]/[free plasma] ratios ranged from 2 to 3, suggesting active transport of DPHM into the CNS.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),,2 to 3,240131,DB01075,Diphenhydramine
,16510542,Plasma protein binding,Plasma protein binding averaged 86.1 +/- 2.3% (mean +/- S.D.) and was not altered with increasing drug dose.,A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),%,86.1,240132,DB01075,Diphenhydramine
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,10.8,240133,DB01075,Diphenhydramine
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,3.6,240134,DB01075,Diphenhydramine
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,5.3,240135,DB01075,Diphenhydramine
,14582745,terminal elimination half lives,"The terminal elimination half lives (h) were 1.58 (1.13-2.58) and 6.11 (4.80-14.1), and the total body clearances (L/h per kg) were 1.42 (1.13-1.74) and 0.79 (0.66-0.90).",Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),h,1.58,242757,DB01075,Diphenhydramine
,14582745,terminal elimination half lives,"The terminal elimination half lives (h) were 1.58 (1.13-2.58) and 6.11 (4.80-14.1), and the total body clearances (L/h per kg) were 1.42 (1.13-1.74) and 0.79 (0.66-0.90).",Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),h,6.11,242758,DB01075,Diphenhydramine
,14582745,total body clearances,"The terminal elimination half lives (h) were 1.58 (1.13-2.58) and 6.11 (4.80-14.1), and the total body clearances (L/h per kg) were 1.42 (1.13-1.74) and 0.79 (0.66-0.90).",Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),[l] / [h·kg],1.42,242759,DB01075,Diphenhydramine
,14582745,total body clearances,"The terminal elimination half lives (h) were 1.58 (1.13-2.58) and 6.11 (4.80-14.1), and the total body clearances (L/h per kg) were 1.42 (1.13-1.74) and 0.79 (0.66-0.90).",Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),[l] / [h·kg],0.79,242760,DB01075,Diphenhydramine
,14582745,volumes of distribution at steady state,The volumes of distribution at steady state (L/kg) were 2.38 (1.58-4.43) and 5.98 (4.60-8.31) and the volumes of the central compartment of the two compartment pharmacokinetic model were 1.58 (0.80-2.54) and 2.48 (1.79-3.17).,Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),[l] / [kg],2.38,242761,DB01075,Diphenhydramine
,14582745,volumes of distribution at steady state,The volumes of distribution at steady state (L/kg) were 2.38 (1.58-4.43) and 5.98 (4.60-8.31) and the volumes of the central compartment of the two compartment pharmacokinetic model were 1.58 (0.80-2.54) and 2.48 (1.79-3.17).,Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),[l] / [kg],5.98,242762,DB01075,Diphenhydramine
,14582745,volumes of the central compartment,The volumes of distribution at steady state (L/kg) were 2.38 (1.58-4.43) and 5.98 (4.60-8.31) and the volumes of the central compartment of the two compartment pharmacokinetic model were 1.58 (0.80-2.54) and 2.48 (1.79-3.17).,Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),,1.58,242763,DB01075,Diphenhydramine
,14582745,volumes of the central compartment,The volumes of distribution at steady state (L/kg) were 2.38 (1.58-4.43) and 5.98 (4.60-8.31) and the volumes of the central compartment of the two compartment pharmacokinetic model were 1.58 (0.80-2.54) and 2.48 (1.79-3.17).,Comparative pharmacokinetics of diphenhydramine in camels and horses after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14582745/),,2.48,242764,DB01075,Diphenhydramine
>or=,17485495,brain-to-plasma concentration ratios,"In addition, the brain-to-plasma concentration ratios were >or=3 in all age groups, suggesting the existence of a transport process for DPHM into the brain.","The use of microdialysis for the study of drug kinetics: central nervous system pharmacokinetics of diphenhydramine in fetal, newborn, and adult sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17485495/),,3,252869,DB01075,Diphenhydramine
,10980511,Total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],138.7,253499,DB01075,Diphenhydramine
,10980511,Total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],165.7,253500,DB01075,Diphenhydramine
,10980511,Total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],116.3,253501,DB01075,Diphenhydramine
,10980511,Total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],38.5,253502,DB01075,Diphenhydramine
,10980511,total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],116.3,253503,DB01075,Diphenhydramine
,10980511,total body clearance,"Total body clearance of DPHM in postnatal lambs (Group A = 138.7 +/- 80.5 mL/min/kg; Group B = 165.7 +/- 51.3 mL/min/kg) was similar to the nonplacental clearance values (i.e., the component of fetal total body clearance that is not due to elimination via the placenta) estimated for fetal lamb (116.3 +/- 49. 6 mL/min/kg), and significantly greater than estimates in adult sheep (38.5 +/- 12.3 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],38.5,253504,DB01075,Diphenhydramine
>,10980511,renal clearance (CL(r),"In addition, Group A DPHM renal clearance (CL(r), >1.80 +/- 1.24 mL/min/kg) was similar to that of the fetus (2.06 +/- 0.24 mL/min/kg), and significantly greater than that for Group B (0.26 +/- 0.17 mL/min/kg) and the adult (0.012 +/- 0.005 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],1.80,253505,DB01075,Diphenhydramine
,10980511,renal clearance (CL(r),"In addition, Group A DPHM renal clearance (CL(r), >1.80 +/- 1.24 mL/min/kg) was similar to that of the fetus (2.06 +/- 0.24 mL/min/kg), and significantly greater than that for Group B (0.26 +/- 0.17 mL/min/kg) and the adult (0.012 +/- 0.005 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],2.06,253506,DB01075,Diphenhydramine
,10980511,renal clearance (CL(r),"In addition, Group A DPHM renal clearance (CL(r), >1.80 +/- 1.24 mL/min/kg) was similar to that of the fetus (2.06 +/- 0.24 mL/min/kg), and significantly greater than that for Group B (0.26 +/- 0.17 mL/min/kg) and the adult (0.012 +/- 0.005 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],0.26,253507,DB01075,Diphenhydramine
,10980511,renal clearance (CL(r),"In addition, Group A DPHM renal clearance (CL(r), >1.80 +/- 1.24 mL/min/kg) was similar to that of the fetus (2.06 +/- 0.24 mL/min/kg), and significantly greater than that for Group B (0.26 +/- 0.17 mL/min/kg) and the adult (0.012 +/- 0.005 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],0.012,253508,DB01075,Diphenhydramine
,10980511,CL(r),"In contrast, similar to the fetal situation, postnatal DPMA CL(r) (Group A = 0.02 +/- 0.02 mL/min/kg; Group B = 0.05 +/- 0.01 mL/min/kg) was significantly less than adult values (0. 53 +/- 0.19 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],0.02,253509,DB01075,Diphenhydramine
,10980511,CL(r),"In contrast, similar to the fetal situation, postnatal DPMA CL(r) (Group A = 0.02 +/- 0.02 mL/min/kg; Group B = 0.05 +/- 0.01 mL/min/kg) was significantly less than adult values (0. 53 +/- 0.19 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],0.05,253510,DB01075,Diphenhydramine
,10980511,CL(r),"In contrast, similar to the fetal situation, postnatal DPMA CL(r) (Group A = 0.02 +/- 0.02 mL/min/kg; Group B = 0.05 +/- 0.01 mL/min/kg) was significantly less than adult values (0. 53 +/- 0.19 mL/min/kg).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),[ml] / [kg·min],0. 53,253511,DB01075,Diphenhydramine
,10980511,CL(r),"Because DPMA is not sequentially metabolized in sheep, the lower CL(r) in postnatal lambs results in longer apparent elimination half-lives of this metabolite (Group A = 90.4 +/- 32.2 h; Group B = 13.13 +/- 11.0 h) compared with that in the adult (2.9 +/- 1.6 h).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),h,90.4,253512,DB01075,Diphenhydramine
,10980511,apparent elimination half-lives,"Because DPMA is not sequentially metabolized in sheep, the lower CL(r) in postnatal lambs results in longer apparent elimination half-lives of this metabolite (Group A = 90.4 +/- 32.2 h; Group B = 13.13 +/- 11.0 h) compared with that in the adult (2.9 +/- 1.6 h).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),h,90.4,253513,DB01075,Diphenhydramine
,10980511,apparent elimination half-lives,"Because DPMA is not sequentially metabolized in sheep, the lower CL(r) in postnatal lambs results in longer apparent elimination half-lives of this metabolite (Group A = 90.4 +/- 32.2 h; Group B = 13.13 +/- 11.0 h) compared with that in the adult (2.9 +/- 1.6 h).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),h,13.13,253514,DB01075,Diphenhydramine
,10980511,apparent elimination half-lives,"Because DPMA is not sequentially metabolized in sheep, the lower CL(r) in postnatal lambs results in longer apparent elimination half-lives of this metabolite (Group A = 90.4 +/- 32.2 h; Group B = 13.13 +/- 11.0 h) compared with that in the adult (2.9 +/- 1.6 h).","Pharmacokinetics and renal excretion of diphenhydramine and its metabolites, diphenylmethoxyacetic acid and diphenhydramine-N-oxide, in developing lambs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10980511/),h,2.9,253515,DB01075,Diphenhydramine
,11270914,oral clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],104,260600,DB01075,Diphenhydramine
,11270914,oral clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],43,260601,DB01075,Diphenhydramine
,11270914,renal clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],4,260602,DB01075,Diphenhydramine
,11270914,renal clearance,"In EMs, diphenhydramine decreased venlafaxine oral clearance from 104+/-60 L/hr to 43+/-23 L/hr (mean +/- SD; p < 0.05) without any effect on renal clearance (4+/-1 L/hr during venlafaxine alone and 4+/-2 L/hr during venlafaxine plus diphenhydramine).",Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270914/),[l] / [h],4,260603,DB01075,Diphenhydramine
,6644246,recovery,"For this purpose a suitable capillary GC-method was developed, which has a detection limit of 2 micrograms/l (serum); the calibration curve is linear between 2.5 and 120 micrograms/l, the reproducibility is always better than 3.6% and the average recovery is about 100.1%.",Quantitative determination of diphenhydramine and orphenadrine in human serum by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6644246/),%,100.1,260737,DB01075,Diphenhydramine
,17944238,flow rate,"To develop and validate a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for the determination of tamsulosin in dog plasma after oral administration of controlled-release tablet of tamsulosin hydrochloride, the samples and the internal standard, diphenhydramine, were extracted from dog plasma by n-hexane-dichloromethane (2 : 1), and separated on a Bonchrom XBP-C18 column using a mobile phase consisted of methanol-acetonitrile-ammonium formate (10 mmol x L(-1)) (30 : 40 : 30, v/v/v), at a flow rate of 0.4 mL x min(-1).",[Determination of tamsulosin in dog plasma by a high sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944238/),[ml] / [min],0.4,265431,DB01075,Diphenhydramine
,19879084,run time,"After sample preparation by liquid-liquid extraction, the analytes and internal standard (diphenhydramine) were analyzed by reversed-phase HPLC on a Venusil Mp-C(18) column (50mmx4.6mm, 5microm) using formic acid:10mM ammonium acetate:methanol (1:40:60, v/v/v) as mobile phase in a run time of 2.6min.","Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879084/),min,2.6,268828,DB01075,Diphenhydramine
,7509380,final elimination half-life,"Taxol plasma concentrations declined in a triexponential fashion, with a final elimination half-life of 10 to 12 hours.",Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7509380/),h,10 to 12,273487,DB01075,Diphenhydramine
